Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Bristol-Myers Squibb1,828 enrolled

Overview

This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.

Study Type

OBSERVATIONAL

Enrollment

1,828

Conditions

Melanoma

Interventions

NivolumabBIOLOGICAL

Melanoma intervention

IpilimumabBIOLOGICAL

Melanoma intervention

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with metastatic melanoma * Initiated at least 1 treatment for metastatic melanoma after 2011 * Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date * Patients who received at least 1 dose of study drug in CA209-067

Locations (1)

Bristol-Myers Squibb

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with less frequent general outpatient visits